NFC
AUTL

Northeast Financial Consultants’s Autolus Therapeutics AUTL Stock Holding History

Northeast Financial Consultants’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,672
Closed -$42K – 322
2022
Q3 		$42K Hold
19,672
– – ﹤0.01% 330
2022
Q2 		$56K Hold
19,672
– – ﹤0.01% 322
2022
Q1 		$82K Sell
19,672
-2,543
-11% -$10.7K ﹤0.01% 382
2021
Q4 		$115K Hold
22,215
– – 0.01% 346
2021
Q3 		$146K Buy
+22,215
New +$140K 0.01% 340

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Northeast Financial Consultants's AUTL Position: Q4 2022 in Review

Northeast Financial Consultants sold out of Autolus Therapeutics (AUTL) in Q4 2022, closing a stake of 19,672 shares — an estimated $42K sold.

Northeast Financial Consultants first reported a position in AUTL in Q3 2021 and held it in 5 quarters. The position peaked at $146K in Q3 2021. 71 funds tracked by Wall St. Rank hold AUTL as of Q4 2022.

  • Northeast Financial Consultants reported no remaining Autolus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Northeast Financial Consultants sold 19,672 Autolus Therapeutics shares in Q4 2022, an estimated $42K.
  • Northeast Financial Consultants first reported a position in Autolus Therapeutics in Q3 2021 and held it in 5 quarters.
  • Northeast Financial Consultants's Autolus Therapeutics position peaked at $146K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2022.

Based on Northeast Financial Consultants's 13F filing for Q4 2022, filed 13 Feb 2023.